A phase II study of neoadjuvant biochemotherapy for stage III melanoma

Cancer
Peter GibbsRene Gonzalez

Abstract

Phase II studies of biochemotherapy (combining interleukin-2, interferon-alpha, and multiagent chemotherapy) have reported high response rates and a significant number of durable complete responses in patients with metastatic melanoma. A pilot Phase II study was performed to explore the safety and activity of neoadjuvant biochemotherapy in patients with Stage III melanoma. Forty-eight patients were enrolled between April 1996 and May 1999. The median age of the patients was 46 years (range, 19-70 years). Two cycles of biochemotherapy were administered prior to and after complete lymph node dissection. Each cycle was comprised of cisplatin, 20 mg/m2 intravenously (i.v.), on Days 1-4; vinblastine, 1.6 mg/m2 i.v., on Days 1-4; dacarbazine, 800 mg/m2 i.v., on Day 1; interleukin-2, 9 x 10(6) IU/m2/day i.v. over 24 hours, on Days 1-4; and interferon-alpha, 5 x 10(6) IU/m2/day subcutaneously, on Days 1-5, every 3 weeks. Twelve patients did not have measurable disease. All patients were evaluable for toxicity and survival. Clinical responses were observed in 14 of 36 patients (38.9%) with measurable disease, including 13 partial responses (36.1%) and 1 complete response (2.8%). Complete pathologic responses were noted in 4 patients (11...Continue Reading

References

Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M KirkwoodR H Blum
May 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S S LeghaN Papadopoulos
Oct 1, 1998·Annals of Surgical Oncology·C P Karakousis
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E GershenwaldM I Ross
Feb 25, 2000·Journal of the American Academy of Dermatology·P WalshR Gonzalez

❮ Previous
Next ❯

Citations

Dec 12, 2002·Molecular Biology of the Cell·Liliana StalevaSeth J Orlow
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kazuo KoyanagiDave S B Hoon
Dec 3, 2003·European Journal of Anaesthesiology·S KvolikI Karner
Apr 24, 2013·Clinics in Dermatology·Diwakar DavarJohn M Kirkwood
Dec 16, 2003·Skinmed·Iris ZalaudekH Peter Soyer
Aug 23, 2011·Journal of Surgical Oncology·Ahmad A TarhiniJohn M Kirkwood
Dec 17, 2014·Cytokine & Growth Factor Reviews·Rossella Di TrolioPaolo Antonio Ascierto
Sep 18, 2016·Critical Reviews in Oncology/hematology·Kristian M KollerJoseph J Drabick
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stergios J MoschosJohn M Kirkwood
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Karl D LewisRene Gonzalez
Dec 12, 2017·Journal of Surgical Oncology·James W JakubMathew S Block
Dec 28, 2018·Journal of Surgical Oncology·Jessica Y Liu, Michael Lowe
Oct 18, 2002·Expert Review of Anticancer Therapy·Lynn E Spitler
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Ahmad A TarhiniSancy Leachman
Jul 23, 2019·Pigment Cell & Melanoma Research·Zeynep ErogluJane Messina
Dec 27, 2019·Current Opinion in Oncology·Hugo Herrscher, Caroline Robert
Apr 25, 2020·Expert Review of Anticancer Therapy·Francesco SpagnoloPaola Queirolo
Dec 23, 2017·Expert Review of Anticancer Therapy·Teresa AmaralClaus Garbe
May 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anna K NowakBruce W S Robinson
Jul 25, 2018·American Journal of Clinical Dermatology·Meredith A McKean, Rodabe N Amaria
Jun 1, 2016·Melanoma Management·Yana G Najjar, John M Kirkwood
Dec 7, 2019·Melanoma Management·James SunZeynep Eroglu
Aug 9, 2019·Therapeutic Advances in Medical Oncology·Arjun KhungerAhmad A Tarhini
May 21, 2015·American Society of Clinical Oncology Educational Book·Ahmad A Tarhini
Jun 1, 2016·Melanoma Management·Eytan Ben-Ami, Jacob Schachter
Jun 27, 2019·Current Treatment Options in Oncology·Maiko Wada-OhnoMasutaka Furue

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.